RCUS241220C20000
- 0.13
- -0.02-13.33%
Arcus Biosciences Newsroom
Barclays Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $29
BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $22
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating
Morgan Stanley Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $36
Arcus Biosciences (RCUS) Gets a Buy From Morgan Stanley
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $20 to $29
BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $22
Arcus Biosciences Analyst Ratings
H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $20
Cautious Hold on Arcus Biosciences Amid Uncertain Trial Outcomes
Arcus Biosciences Is Maintained at Overweight by Barclays
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $20 to $46
Arcus Biosciences Analyst Ratings
Buy Rating on Arcus Biosciences Driven by Promising Clinical Data and Potential of Drug Candidate 'Cas'
Arcus Biosciences' Casdatifan Shows Promise but Requires Caution: Hold Rating Due to Inconclusive Study Results
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating
Arcus Biosciences Initiated at Neutral by HC Wainwright & Co.
Arcus Biosciences Analyst Ratings
H.C. Wainwright Initiates Arcus Biosciences(RCUS.US) With Hold Rating, Announces Target Price $20
Barclays Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $25